Literature DB >> 23094685

Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate.

Ewa Selg1, Pär Ewing, Fernando Acevedo, Carl-Olof Sjöberg, Ake Ryrfeldt, Per Gerde.   

Abstract

BACKGROUND: The isolated perfused rat lung (IPL) is a suitable model for studying lung-specific pharmacokinetics (PK) of inhaled drugs. So far, little has been known, however, whether the PK measured in the ex vivo organ corresponds to the PK measured in similarly exposed animals in vivo, in particular the endotracheally intubated rat (EIR). The purpose of the current research was to compare the PK of inhaled corticosteroid fluticasone furoate (FF) in the IPL and the EIR.
METHOD: Aerosols of FF with mass median aerodynamic diameters ranging from 2.2 to 3.2 μm were generated with the DustGun aerosol generator. The IPL, perfused in the single-pass mode, was exposed via inhalation to 5.6 and 46 μg of FF. Following inhalation, the perfusate was repeatedly sampled for 100 min, after which the lungs were recovered for quantitation of remaining FF. Two groups of EIR were also exposed via inhalation to 7 μg of FF. One group was immediately euthanized for determination of the initial deposition of FF in the lungs. From the second group, four venous blood samples were drawn up to 4 hr after exposure. The animals were then sacrificed for determination of FF remaining in the lungs.
RESULTS: Following inhalation, FF was slowly disappearing from both the IPL and the lungs of the EIR, with a half-life of pulmonary retention of 4.3-4.9 hr for all three exposure series. For the low exposure levels, the concentration curve of FF in the IPL perfusate was similar in shape to that in venous blood of the EIR, with a Cmax of 1.0 and 0.8 nM for the IPL and the EIR, respectively.
CONCLUSIONS: The results indicate that the IPL and the EIR, when used jointly in PK studies, can provide a detailed characterization of inhaled drugs or toxicants.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23094685     DOI: 10.1089/jamp.2012.0971

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  6 in total

1.  Bioavailability of inhaled or ingested PFOA adsorbed to house dust.

Authors:  Åsa Gustafsson; Bei Wang; Per Gerde; Åke Bergman; Leo W Y Yeung
Journal:  Environ Sci Pollut Res Int       Date:  2022-06-14       Impact factor: 5.190

2.  Validating excised rodent lungs for functional hyperpolarized xenon-129 MRI.

Authors:  David M L Lilburn; Theodore Hughes-Riley; Joseph S Six; Karl F Stupic; Dominick E Shaw; Galina E Pavlovskaya; Thomas Meersmann
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

3.  Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model.

Authors:  Chris D Edwards; Chris Luscombe; Peter Eddershaw; Edith M Hessel
Journal:  Pharm Res       Date:  2016-07-11       Impact factor: 4.200

4.  Development of Combining of Human Bronchial Mucosa Models with XposeALI® for Exposure of Air Pollution Nanoparticles.

Authors:  Jie Ji; Anna Hedelin; Maria Malmlöf; Vadim Kessler; Gulaim Seisenbaeva; Per Gerde; Lena Palmberg
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

5.  A novel method for studying airway hyperresponsiveness in allergic guinea pigs in vivo using the PreciseInhale system for delivery of dry powder aerosols.

Authors:  A J Lexmond; S Keir; W Terakosolphan; C P Page; B Forbes
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

Review 6.  Modifying and Integrating in vitro and ex vivo Respiratory Models for Inhalation Drug Screening.

Authors:  Aylin Cidem; Peta Bradbury; Daniela Traini; Hui Xin Ong
Journal:  Front Bioeng Biotechnol       Date:  2020-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.